SCHEMBL6955382

SCHEMBL6955382

CCc1nc(OCC(F)(F)F)c([N+](=O)[O-])c(N2CCc3ccccc3CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGMT P16455 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 5/20 0.35
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
GPR55 Q9Y2T6 1/20 0.34
LMNA P02545 2/20 0.34
HRH4 Q9H3N8 1/20 0.34
POLB P06746 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
TSHR P16473 1/20 0.33
MET P08581 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6947678 0.88 MGMT (0.42) MGMTSMN1; SMN2HTTMAPTMEN1
SCHEMBL6957503 0.77 MGMT (0.44) MGMTSMN1; SMN2HTTMAPTMEN1
SCHEMBL6953559 0.74 MAPT (0.49) MGMTSMN1; SMN2HTTMAPTMEN1
SCHEMBL6955400 0.73 PIK3CD (0.38) HTTMAPTMEN1KMT2ALMNA
SCHEMBL4422945 0.73 MGMT (0.41) MGMTMAPTGPR119CYP1A2CYP3A4
SCHEMBL6951003 0.72 MGMT (0.42) MGMTSMN1; SMN2HTTMAPTMEN1
SCHEMBL6945292 0.72 MGMT (0.45) MGMTSMN1; SMN2HTTMAPTMEN1
SCHEMBL6955505 0.72 MGMT (0.47) MGMTSMN1; SMN2HTTMAPTMEN1
SCHEMBL6948575 0.71 MGMT (0.42) MGMTSMN1; SMN2HTTMAPTMEN1
SCHEMBL6949472 0.71 MGMT (0.42) MGMTSMN1; SMN2HTTMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed